Extended Data Fig. 7: Differential phase shift profile for the inverse agonist UCSF7447 compared to the agonist melatonin and a prototype antagonist (luzindole) across the circadian cycle.
From: Virtual discovery of melatonin receptor ligands to modulate circadian rhythms
a–c, C3H/HeN mice were kept in constant dark and treated with vehicle, melatonin, luzindole or UCSF7447 (all treatments were 30 μg per mouse except for luzindole, which was 300 μg per mouse, subcutaneously). Mice were treated at CT 2, 6 or 10 (10, 6 or 2 h before the onset of running wheel activity) for three consecutive days (Methods). a, CT 2 phase shift data were compared using one-way ANOVA (F3,11 = 28.16, P = 1.85 × 10−5). b, CT 6 phase shift data were compared using one-way ANOVA (F3,26 = 0.61, P = 0.61). c, CT 10 phase shift data were compared using one-way ANOVA (F3,17 = 35.13, P = 1.66 × 10−7). All multiple comparisons were made compared with vehicle using a Dunnet’s post hoc test (P < 0.05). Values for melatonin and UCSF7447 at CT 10 were pooled from previous data for comparison to luzindole. Data are mean ± s.e.m. ****P < 0.0001 for comparisons with vehicle. All treatments were given by subcutaneous injection.
